New treatment options for autoimmune bullous diseases (PubMed, Dermatologie (Heidelb)) - Sep 23, 2026 - "Rituximab is also approved for moderate to severe pemphigus vulgaris...Current therapeutic approaches focus primarily on enhancing the efficacy of B‑cell depletion in pemphigus vulgaris/foliaceus, as well as on blocking specific inflammatory mediators in bullous pemphigoid. Further efforts are required to conduct more studies within this group of diseases and to fully realize the potential of more effective drugs with improved side-effect profiles."
Journal • Bullous Pemphigoid • Dermatology • Dermatopathology • Immunology • Pemphigus Vulgaris
|
|
Enno Schmidt; Nina van Beek
|